Clinical efficacy of dual trigger with human chorionic gonadotropin and a gonadotropin-releasing hormone agonist for women undergoing fertility preservation.

Hong YH, Kim SK, Lee JR, Jee BC, Suh CS

Reproductive medicine and biology1 Jan 2022Cited by 10 (Europe PMC)

PMID35386366PMCIDPMC8967295DOI10.1002/rmb2.12440PepBankPUB-35386366

Read at source PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

01HumanObservational studyEfficacy outcome
In patients undergoing fertility preservation, adding triptorelin to rhCG was not linked to a different total oocyte count versus rhCG alone.
In plain wordsIn patients undergoing fertility preservation, total oocyte counts were similar with triptorelin plus rhCG and rhCG alone.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
No significant changeTotal oocyte count
Study
n = 293
Comparator
rhCG alone
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
0.2 mgAs given in this study (human).
Source sentences
Summary
There was no significant difference in the baseline characteristics or the number of total and mature oocytes between the two groups.
2 context sentences(design, population, supporting numbers)
Summary · context
A total of 373 cycles in 293 patients undergoing controlled ovarian stimulation (COS) for FP using a gonadotropin-releasing hormone (GnRH) antagonist protocol were enrolled.
Summary · context
The control group (n = 225) received 250 µg of recombinant human chorionic gonadotropin (rhCG) while the study group (n = 148) received 250 µg of rhCG and 0.2 mg of triptorelin for triggering.
Report a problemFND-3538636601
02HumanObservational studyEfficacy outcome
In patients undergoing fertility preservation, adding triptorelin to rhCG was not linked to a different mature oocyte count versus rhCG alone.
In plain wordsIn patients undergoing fertility preservation, mature oocyte counts were similar with triptorelin plus rhCG and rhCG alone.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
No significant changeMature oocyte count
Study
n = 293
Comparator
rhCG alone
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
0.2 mgAs given in this study (human).
Source sentences
Summary
There was no significant difference in the baseline characteristics or the number of total and mature oocytes between the two groups.
2 context sentences(design, population, supporting numbers)
Summary · context
A total of 373 cycles in 293 patients undergoing controlled ovarian stimulation (COS) for FP using a gonadotropin-releasing hormone (GnRH) antagonist protocol were enrolled.
Summary · context
The control group (n = 225) received 250 µg of recombinant human chorionic gonadotropin (rhCG) while the study group (n = 148) received 250 µg of rhCG and 0.2 mg of triptorelin for triggering.
Report a problemFND-3538636602
03HumanObservational studyEfficacy outcome
In fertility preservation cycles with endometrioma, subgroup analysis showed results similar to the overall comparison, with no significant difference in oocyte numbers between triptorelin plus rhCG and rhCG alone.
In plain wordsIn fertility preservation cycles with endometrioma, oocyte results were similar with triptorelin plus rhCG and rhCG alone.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
No significant changeOocyte numbers (total and mature) in endometrioma subgroup
Study
n = 104
Comparator
rhCG alone
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
0.2 mgAs given in this study (human).
Source sentences
Summary
Subgroup analyses for women with endometrioma or DOR showed similar results.
4 context sentences(design, population, supporting numbers)
Summary · context
There was no significant difference in the baseline characteristics or the number of total and mature oocytes between the two groups.
Summary · context
Subgroup analyses were performed for stimulation cycles with diminished ovarian reserve (DOR; anti-Müllerian hormone (AMH) levels n = 86), with endometrioma (n = 104), or with breast cancer and endometrial cancer using 5 mg of letrozole during the COS cycles (n = 84).
Summary · context
A total of 373 cycles in 293 patients undergoing controlled ovarian stimulation (COS) for FP using a gonadotropin-releasing hormone (GnRH) antagonist protocol were enrolled.
Summary · context
The control group (n = 225) received 250 µg of recombinant human chorionic gonadotropin (rhCG) while the study group (n = 148) received 250 µg of rhCG and 0.2 mg of triptorelin for triggering.
Report a problemFND-3538636603
04HumanObservational studyEfficacy outcome
In fertility preservation cycles with diminished ovarian reserve, subgroup analysis showed results similar to the overall comparison, with no significant difference in oocyte numbers between triptorelin plus rhCG and rhCG alone.
In plain wordsIn cycles with diminished ovarian reserve, oocyte results were similar with triptorelin plus rhCG and rhCG alone.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
No significant changeOocyte numbers (total and mature) in diminished ovarian reserve subgroup
Study
n = 86
Comparator
rhCG alone
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
0.2 mgAs given in this study (human).
Source sentences
Summary
Subgroup analyses for women with endometrioma or DOR showed similar results.
4 context sentences(design, population, supporting numbers)
Summary · context
There was no significant difference in the baseline characteristics or the number of total and mature oocytes between the two groups.
Summary · context
Subgroup analyses were performed for stimulation cycles with diminished ovarian reserve (DOR; anti-Müllerian hormone (AMH) levels n = 86), with endometrioma (n = 104), or with breast cancer and endometrial cancer using 5 mg of letrozole during the COS cycles (n = 84).
Summary · context
A total of 373 cycles in 293 patients undergoing controlled ovarian stimulation (COS) for FP using a gonadotropin-releasing hormone (GnRH) antagonist protocol were enrolled.
Summary · context
The control group (n = 225) received 250 µg of recombinant human chorionic gonadotropin (rhCG) while the study group (n = 148) received 250 µg of rhCG and 0.2 mg of triptorelin for triggering.
Report a problemFND-3538636604
05HumanObservational studyEfficacy outcome
In cancer patients using letrozole for fertility preservation, triptorelin plus rhCG was linked to more mature oocytes than rhCG alone.
In plain wordsIn cancer patients using letrozole, triptorelin plus rhCG was linked to more mature oocytes than rhCG alone.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
IncreaseMature oocyte count in cancer patients using letrozole
Study
n = 84
Comparator
rhCG alone
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
0.2 mgAs given in this study (human).
Measurements
Mature oocytes
6.9 oocytes
dual trigger, cancer patients using letrozole
Mature oocytes
4.6 oocytes
rhCG alone, cancer patients using letrozole
Source sentences
Summary
However, the dual trigger group had a significantly higher number of mature oocytes than the rhCG trigger group in breast and endometrial cancer patients using letrozole during the COS cycles (6.9 ± 6.0 vs. 4.6 ± 3.6, p = 0.034).
3 context sentences(design, population, supporting numbers)
Summary · context
Subgroup analyses were performed for stimulation cycles with diminished ovarian reserve (DOR; anti-Müllerian hormone (AMH) levels n = 86), with endometrioma (n = 104), or with breast cancer and endometrial cancer using 5 mg of letrozole during the COS cycles (n = 84).
Summary · context
A total of 373 cycles in 293 patients undergoing controlled ovarian stimulation (COS) for FP using a gonadotropin-releasing hormone (GnRH) antagonist protocol were enrolled.
Summary · context
The control group (n = 225) received 250 µg of recombinant human chorionic gonadotropin (rhCG) while the study group (n = 148) received 250 µg of rhCG and 0.2 mg of triptorelin for triggering.
Report a problemFND-3538636605
06HumanObservational studyEfficacy outcome
In women undergoing fertility preservation, the maturation rate was higher with triptorelin plus rhCG than with rhCG alone, but the difference was not statistically significant (59.3 vs 50.0, p = 0.124).
In plain wordsIn women undergoing fertility preservation, the maturation rate was higher with triptorelin plus rhCG than with rhCG alone, but not significantly.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
No significant changeOocyte maturation rate
Study
n: not reported in source
Comparator
rhCG alone
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
0.2 mgAs given in this study (human).
Measurements
Maturation rate
59.3 not stated
dual trigger
Maturation rate
50 not stated
rhCG alone
Source sentences
Summary
The maturation rate was higher in the dual trigger group, although the difference was not statistically significant (59.3 ± 26.7 vs. 50.0 ± 28.0, p = 0.124).
2 context sentences(design, population, supporting numbers)
Summary · context
However, the dual trigger group had a significantly higher number of mature oocytes than the rhCG trigger group in breast and endometrial cancer patients using letrozole during the COS cycles (6.9 ± 6.0 vs. 4.6 ± 3.6, p = 0.034).
Summary · context
The control group (n = 225) received 250 µg of recombinant human chorionic gonadotropin (rhCG) while the study group (n = 148) received 250 µg of rhCG and 0.2 mg of triptorelin for triggering.
Report a problemFND-3538636606

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.